-
QUALITY-ADJUSTED LIFE EXPECTANCY (QALE) BY ETHNICITY IN ENGLAND: UPDATED ESTIMATES USING THE NEW EQ-5D-5L VALUE SET
Aug 11, 2026, 17:16 PM -
CAN AI-ASSISTED SLRS MEET HTA STANDARDS? EVIDENCE FROM A NICE SINGLE TECHNOLOGY APPRAISAL
Aug 11, 2026, 17:16 PM -
REDUCING FRAILTY IN OLDER ADULTS IN THE UK: ESTIMATED COST SAVINGS AND QUALITY-OF-LIFE BENEFITS
Aug 11, 2026, 17:16 PM -
IDENTIFYING FIT-FOR-PURPOSE OBSERVER REPORTED OUTCOMES BY CROSS COMPARING REGULATORY PERSPECTIVES AND VALIDITY EVIDENCE IN INTERCONNECTED DATABASES
Aug 11, 2026, 17:16 PM -
HEALTH AND ECONOMIC IMPACT OF EXTENDING HPV VACCINATION TO ADULTS 20-26 YEARS OF AGE IN FRANCE: A MODELING STUDY
Aug 11, 2026, 17:16 PM -
IMPACT OF MEDICARE PRICE NEGOTIATION ON COMPARATIVE COST-EFFECTIVENESS OF IBRUTINIB, ACALABRUTINIB, AND ZANUBRUTINIB IN CHRONIC LYMPHOCYTIC LEUKEMIA: A SYSTEMATIC REVIEW AND NETWORK META-ANALYSIS
Aug 11, 2026, 17:16 PM -
SOCIOECONOMIC BURDEN OF ATHEROSCLEROTIC CARDIOVASCULAR DISEASE IN SPAIN: WHEN CHRONIC KIDNEY DISEASE AND INFLAMMATORY RISK CO-OCCUR
Aug 11, 2026, 17:16 PM -
OVERALL SURVIVAL OF SUGEMALIMAB PLUS CHEMOTHERAPY VERSUS FIRST-LINE PD-1/PD-L1 INHIBITOR REGIMENS IN METASTATIC NSCLC: AN ETHNICITY-ADJUSTED INDIRECT TREATMENT COMPARISON
Aug 11, 2026, 17:16 PM -
SOCIOECONOMIC BURDEN OF HER2-POSITIVE BREAST CANCER IN ALGERIA: A PREVALENCE-BASED COST-OF-ILLNESS ANALYSIS
Aug 11, 2026, 17:16 PM -
ECONOMIC POSITIONING OF SURGERY WITH ABSORBABLE STEROID-ELUTING SINUS IMPLANTS VERSUS DUPILUMAB IN SEVERE CRSWNP: AN ITALIAN NATIONAL HEALTH SERVICE PAYER PERSPECTIVE
Aug 11, 2026, 17:16 PM -
PROJECTING DISPARITIES IN THE CLINICAL AND ECONOMIC BURDEN OF COPD BY NEIGHBOURHOOD-LEVEL SOCIOECONOMIC DEPRIVATION IN THE UNITED STATES
Aug 11, 2026, 17:16 PM -
PHYSICIAN DECISION LOGIC IN RURAL HEALTHCARE NETWORKS - A CROSS-SECTIONAL ANALYSIS OF REFERRAL AND ADMISSION PATTERNS
Aug 11, 2026, 17:16 PM -
COST-CONSEQUENCE AND BUDGET IMPACT OF PATIENT BLOOD MANAGEMENT IN TWO CHINESE HOSPITALS
Aug 11, 2026, 17:16 PM -
ENVIRONMENTAL IMPACT OF RELAPSING-REMITTING MULTIPLE SCLEROSIS TREATMENTS ACROSS EUROPE: IMPLICATIONS FOR SUSTAINABLE PRESCRIPTION
Aug 11, 2026, 17:16 PM -
REAL-WORLD BOTTOM-UP COST-OF-ILLNESS ANALYSIS OF TYPE 2 DIABETES MELLITUS IN A SAUDI TERTIARY HOSPITAL
Aug 11, 2026, 17:16 PM -
REAL-WORLD TREATMENT PATTERNS AND ATTACK BURDEN IN HEREDITARY ANGIOEDEMA: FINDINGS FROM GERMAN CLAIMS DATA AND MEDICAL CHARTS
Aug 11, 2026, 17:16 PM -
IS THERE AN IMPLICIT COST-EFFECTIVENESS THRESHOLD IN FRANCE? EVIDENCE FROM CEESP ASSESSMENTS (2021-2026)
Aug 11, 2026, 17:16 PM -
AN INTEGRATED DISEASE CONCEPTUAL MODEL OF MULTIPLE SCLEROSIS (MS) FROM THE PATIENTS' PERSPECTIVE: A MULTINATIONAL QUALITATIVE STUDY
Aug 11, 2026, 17:16 PM -
MID- AND LONG-TERM NUMBER NEEDED TO TREAT FOR TILDRAKIZUMAB 200 MG IN MODERATE-TO-SEVERE PLAQUE PSORIASIS PATIENTS WITH BODY WEIGHT =90 KG
Aug 11, 2026, 17:16 PM -
CAN ARTIFICIAL INTELLIGENCE RELIABLY PERFORM TITLE-ABSTRACT SCREENING FOR SYSTEMATIC LITERATURE REVIEWS?
Aug 11, 2026, 17:16 PM
